Nuvaira
Medical device company developing a bronchoscopic, catheter-delivered lung denervation therapy for COPD. The organization conducts preclinical research and multicenter clinical trials (including randomized, double-blind, sham-controlled studies), develops single-use bronchoscopic catheters and a procedure console with coolant circulation, and supports clinical data management, regulatory submissions, and manufacturing process validation for device development.
Industries
Nr. of Employees
medium (51-250)
Patents
Compact delivery pulmonary treatment systems and methods for improving pulmonary function
US-12708440-B2
View DetailsNon-invasive and minimally invasive denervation methods and systems for performing the same
US-12343060-B2
View DetailsSystems, apparatuses, and methods for treating tissue and controlling stenosis
US-12290309-B2
View Details
Compact delivery pulmonary treatment systems and methods for improving pulmonary function
US-12708440-B2
View DetailsNon-invasive and minimally invasive denervation methods and systems for performing the same
US-12343060-B2
View DetailsSystems, apparatuses, and methods for treating tissue and controlling stenosis
US-12290309-B2
View DetailsProducts
Bronchoscopic lung denervation system (catheter and console)
A system comprised of a disposable bronchoscopic catheter (multiple sizes), an esophageal cooling catheter for protection, and a procedure console that circulates coolant and controls RF energy delivery via a user interface.
Bronchoscopic lung denervation system (catheter and console)
A system comprised of a disposable bronchoscopic catheter (multiple sizes), an esophageal cooling catheter for protection, and a procedure console that circulates coolant and controls RF energy delivery via a user interface.
Services
Sponsor, design and execute multicenter randomized, double-blind, sham-controlled trials and coordinate investigator sites.
Design and validate clinical databases, develop CRFs/eCRFs and manage clinical data quality, vendor oversight and safety reporting.
Sponsor, design and execute multicenter randomized, double-blind, sham-controlled trials and coordinate investigator sites.
Design and validate clinical databases, develop CRFs/eCRFs and manage clinical data quality, vendor oversight and safety reporting.
Expertise Areas
- Interventional pulmonology (bronchoscopic therapies)
- Clinical trial management for medical devices
- Device engineering for bronchoscopic delivery systems
- Radiofrequency ablation therapy development
Key Technologies
- Radiofrequency (RF) ablation
- Bronchoscopic catheter delivery systems
- Active coolant circulation for tissue protection
- Esophageal cooling catheter technology
News & Updates
Announcement of the first patient treated in a pivotal randomized trial evaluating targeted lung denervation in a COPD phenotype characterized by lung hyperinflation and low emphysema; notes appointment of a new Chief Strategy Officer and recent funding to complete the trial.
Summary of AIRFLOW-3 trial design (randomized, double-blind, sham-controlled) and findings indicating improvements in pre-specified measures of lung function and dyspnea in intent-to-treat analyses and subgroup benefits in patients with lung hyperinflation and low emphysema.
Completed multiple clinical studies (including Phase 1–3 elements), treated over 500 patients across studies, and produced peer-reviewed publications documenting safety and efficacy endpoints.
Announcement of the first patient treated in a pivotal randomized trial evaluating targeted lung denervation in a COPD phenotype characterized by lung hyperinflation and low emphysema; notes appointment of a new Chief Strategy Officer and recent funding to complete the trial.
Summary of AIRFLOW-3 trial design (randomized, double-blind, sham-controlled) and findings indicating improvements in pre-specified measures of lung function and dyspnea in intent-to-treat analyses and subgroup benefits in patients with lung hyperinflation and low emphysema.
Completed multiple clinical studies (including Phase 1–3 elements), treated over 500 patients across studies, and produced peer-reviewed publications documenting safety and efficacy endpoints.